Mechanisms of β-N-methylamino-L-alanine induced neurotoxicity

References

• Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers such as memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004; 1:101–10.
   PubMedGoogle Scholar
• Ross SM, Seelig M, Spencer PS. Specific antagonism of excitotoxic action of ‘uncommon’ amino acids assayed in organotypic mouse cortical cultures. Brain Res. 1987; 425:120–7.
   PubMed Web of Science ®Google Scholar
• Weiss JH, Choi DW. Beta-N-methylamino-L-alanine neurotoxicity: requirement for bicarbonate as a cofactor. Science. 1988; 241:973–5.
   PubMed Web of Science ®Google Scholar
• Weiss JH, Koh JY, Choi DW. Neurotoxicity of ß-N-methylamino-L-alanine (BMAA) and ß-N-oxalylamino-L-alanine (BOAA) on cultured cortical neurons. Brain Res. 989; 497:64–71.
   Google Scholar
• Zeevalk GD, Nicklas WJ. Acute excitotoxicity in chick retina caused by the unusual amino acids BOAA and BMAA: effects of MK-801 and kynurenate. Neurosci Lett. 1989; 102:284–90.
   PubMed Web of Science ®Google Scholar
• Pai KS, Shankar SK, Ravindranath V. Billion-fold difference in the toxic potencies of two excitatory plant amino acids, L-BOAA and L-BMAA: biochemical and morphological studies using mouse brain slices. Neurosci Res. 1993; 17:241–8.
   PubMedGoogle Scholar
• Lobner D, Piana PM, Salous AK, Peoples RW. ß-N-methylamino-L-alanine enhances neurotoxicity through multiple mechanisms. Neurobiol Dis. 2007; 25:360–6.
   PubMed Web of Science ®Google Scholar
• Rakonczay Z, Matsuoka Y, Giacobini E. Effects of L-ß-N-methylamino-L-alanine (L-BMAA) on the cortical cholinergic and glutamatergic systems of the rat. J Neurosci Res. 1991; 29:121–6.
   PubMedGoogle Scholar
• Smith SE, Meldrum BS. Receptor site specificity for the acute effects of ß-N-methylamino-alanine in mice. Eur J Pharmacol. 1990; 187:131–4.
   PubMed Web of Science ®Google Scholar
• Rao SD, Banack SA, Cox PA, Weiss JH. BMAA selectively injures motor neurons via AMPA/kainate receptor activation. Exp Neurol. 2006; 201:244–52.
   PubMed Web of Science ®Google Scholar
• Weiss JH, Turetsky D, Wilke G, Choi DW. AMPA/kainate receptor-mediated damage to NADPH-diaphorase-containing neurons is Ca2+ dependent. Neurosci Lett. 1994; 167:93–6.
   PubMedGoogle Scholar
• Carriedo SG, Yin HZ, Lamberta R, Weiss JH. In vitro kainate injury to large, SMI-32(+) spinal neurons is Ca2+ dependent. Neuroreport. 1995; 19:945–8.
   Google Scholar
• Strasser U, Lobner D, Behrens MM, Canzoniero LM, Choi DW. Antagonists for group I mGluRs attenuate excitotoxic neuronal death in cortical cultures. Eur J Neurosci. 1998; 10:2848–55.
   PubMed Web of Science ®Google Scholar
• Manzoni OJ, Prezeau L, Bockaert J. ß-N-methylamino-L-alanine is a low-affinity agonist of metabotropic glutamate receptors. Neuroreport. 1991; 2:609–11.
   PubMed Web of Science ®Google Scholar
• Buisson A, Choi DW. The inhibitory mGluR agonist, S-4-carboxy-3-hydroxy-phenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death. Neuropharmacology. 1995; 34:1081–7.
   PubMedGoogle Scholar
• Genazzani AA, Casabona G, L'Episcopo MR, Condorelli DF, Dell' Albani P, Shinozaki H, Nicoletti F. Characterization of metabotropic glutamate receptors negatively linked to adenylyl cyclase in brain slices. Brain Res. 1993; 622:132–8.
   PubMedGoogle Scholar
• Zapata J, Hjelmhaug JA, Lobner D. Role of the cystine-glutamate antiporter in β-N-methylamino-L-alanine (BMAA) toxicity. Soc Neurosci Abs. 2007; 604:9.
   Google Scholar
• Fogal B, Li J, Lobner D, McCullough LD, Hewett SJ. System X(c)- activity and astrocytes are necessary for interleukin-1 beta-mediated hypoxic neuronal injury. J Neurosci. 2007; 27:10094–105.
   PubMedGoogle Scholar
• Piani D, Fontana A. Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J Immunol. 1994; 152:3578–85.
   PubMed Web of Science ®Google Scholar
• Qin S, Colin C, Hinners I, Gervais A, Cheret C, Mallat M. system xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. J Neurosci. 2006; 26:3345–56.
   PubMed Web of Science ®Google Scholar
• Murch SJ, Cox PA, Banack SA, Steele JC, Sacks OW. Occurrence of ß-methylamino-L-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand. 2004; 110:267–9.
   PubMed Web of Science ®Google Scholar
• Uversky VN. Alpha-synuclein misfolding and neurodegenerative diseases. Curr Protein Pept Sci. 2008; 9:507–40.
   PubMed Web of Science ®Google Scholar
• Gotz J, Schild A, Hoerndli F, Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci. 2004; 11:453–65.
   Google Scholar
• Gerlach M, Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm. 1996; 103:987–1041.
   PubMed Web of Science ®Google Scholar
• Johannessen JN, Adams JD, Schuller HM, Bacon JP, Markey SP. 1-methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. Life Sci. 1986; 38:743–9.
   PubMed Web of Science ®Google Scholar
• Kwon YS, Koh JY, Song DK, Kim HC, Kwon MS, Choi YS, Wie MB. Danthron inhibits the neurotoxicity induced by various compounds causing oxidative damages including beta-amyloid (25-35) in primary cortical cultures. Biol Pharm Bull. 2004; 27:723–6.
   PubMedGoogle Scholar
• Karamyan VT, Speth RC. Animal models of BMAA neurotoxicity: a critical review. Life Sci. 2008; 82:233–46.
   PubMed Web of Science ®Google Scholar
• Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Brain Res Rev. 1997; 25:335–58.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang H, Shenvi S, Hagen TM, Liu RM. Glutathione metabolism during aging and in Alzheimer's disease. Ann N Y Acad Sci. 2004; 1019:346–9.
   PubMed Web of Science ®Google Scholar
• Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother. 2000; 62:236–49.
   Google Scholar